First name,Last name,Preferred title,Overview,Position,Department,Individual
James,Womack,Distinguished Professor,"Comparative mammalian genomics with emphasis on bovids and laboratory animals. Study of evolution of gene families and genomic variation underlying disease resistance. Investigation of genetic mechanisms in innate immunity with focus on livestock, select agents, and agricultural biosecurity.",Distinguished Professor,Veterinary Pathobiology,https://scholars.library.tamu.edu/vivo/display/n0e1a49e2
Guoyao,Wu,Distinguished Professor,"Dr. Wu teaches graduate courses in protein metabolism and nutritional biochemistry. He conducts research in protein and amino acid metabolism at molecular, cellular, and whole body levels . The animal models used in his research include cattle, chicks, pigs, rats, sheep, fish, and shrimp. He has also conducted research on amino acid nutrition in humans.",Faculty Fellow||University Faculty Fellow||Distinguished Professor||Senior Faculty Fellow||Distinguished Professor,Veterinary Integrative Biosciences||Animal Science||Texas A&M AgriLife Research||Texas A&M AgriLife Research||Nutrition,https://scholars.library.tamu.edu/vivo/display/n169f9a74
Roderick,Dashwood,University Distinguished Professor,"Research integrates multiomic, genetic, epigenetic and immune approaches for precision oncology. Epigenetic readers, writers and erasers that reversibly regulate immune players in the antigen presentation pathway are of current mechanistic interest. Molecular and cell-based assays are combined with preclinical models coupled to polypectomy. Clinical specimens and organoids from patients undergoing colectomy provide for human translation. Supported by the NCI, NINDS/NIA, and the John S. Dunn Foundation.",John S. Dunn Chair in Disease Prevention||Distinguished Professor||Director,Institute of Biosciences and Technology||Center for Epigenetics and Disease Prevention||School of Medicine,https://scholars.library.tamu.edu/vivo/display/n7a63dbe7
Stephen,Safe,Distinguished Professor,The aryl hydrocarbon receptor (AhR) is a nuclear helix-loop-helix transcription factor which forms a ligand-induced nuclear heterodimer with the AhR nuclear translocator (Arnt) protein. Research in this laboratory is focused on the molecular mechanism of crosstalk between the AhR and estrogen receptor (ER) signaling pathways in which the AhR inhibits estrogen-induced gene expression. The antiestrogenic activities of some AhR agonists are also being developed as drugs for clinical treatment of breast and endometrial cancers in women. Research on estrogen-dependent gene expression in various cancer cell lines is focused on analysis of several gene promoters to determine the mechanisms of ERa and ERb action. This includes several genes that are activated through interactions of the ER with Sp1 protein and other DNA-bound transcription factors.,Distinguished Professor||Distinguished Professor||Syd Kyle Chair,School of Veterinary Medicine and Biomedical Sciences||Biochemistry and Biophysics||Veterinary Physiology and Pharmacology,https://scholars.library.tamu.edu/vivo/display/nb20fdbd9
Richard,Gomer,Distinguished Professor,"Our laboratory is working on three areas of biomedicine, trying to move observations from basic research into the clinic. First, we are studying how the sizes of tissues and tumors are regulated, and how this can be manipulated for therapeutic purposes. As a model system, we are using the simple eukaryote Dictyostelium discoideum, which allows us to combine techniques such as biochemistry, genetics, computer modeling, and cell biology to study tissue size regulation. We have found that a secreted protein as well as the unusual molecule polyphosphate are signals in negative feedback loops that inhibit Dictyostelium cell proliferation, and we are studying the signal transduction pathway to understand similar mechanisms in humans.
Second, we are studying how some secreted proteins can make cells move away from the source of the signal. We found such a signal (called a chemorepellent) in Dictyostelium, and then found a similar signal in humans. We are working to understand the signal transduction pathway for both. The human signal repels neutrophils, and we found that this can be used therapeutically in mouse models of neutrophil-driven diseases such as rheumatoid arthritis and acute respiratory distress syndrome.
Third, we have found that a human blood protein called Serum Amyloid P (SAP) regulates a key step in the formation of scar tissue as well as the formation of the scar-like lesions in fibrosing diseases such as congestive heart failure and pulmonary fibrosis. We are studying this mechanism, and a biotech company (Promedior, now sold to Roche) we co-founded is testing SAP as a therapy for fibrosis in patients in a Phase 3 trials.",Distinguished Professor,Biology,https://scholars.library.tamu.edu/vivo/display/nf41f3898